RiverPark Advisors’s Transmedics TMDX Stock Holding History

RiverPark Advisors’s Portfolio TMDX Stock Details TMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$67.1K	Sell	675 -9	-1%	-$1.17K	0.02%	126
2025 Q4	$83.2K	Buy	684 +298	+77%	+$37.4K	0.02%	125
2025 Q3	$43.3K	Sell	386 -577	-60%	-$67.5K	0.02%	122
2025 Q2	$129K	Buy	+963	New	+$106K	0.08%	90
2025 Q1	–	Sell	-293	Closed	-$118K	–	147
2024 Q4	$118K	Sell	293 -3,404	-92%	-$317K	0.09%	98
2024 Q3	$580K	Sell	3,697 -765	-17%	-$118K	0.47%	49
2024 Q2	$672K	Sell	4,462 -1,620	-27%	-$194K	0.56%	45
2024 Q1	$450K	Buy	6,082 +4,763	+361%	+$393K	0.37%	56
2023 Q4	$104K	Buy	1,319 +215	+19%	+$13K	0.1%	54
2023 Q3	$60.4K	Buy	+1,104	New	+$79.5K	0.05%	63

Other funds holding TMDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RiverPark Advisors's TMDX Position: Q1 2026 in Review

RiverPark Advisors reduced its Transmedics (TMDX) stake by 1.3% in Q1 2026, selling an estimated $1.17K and leaving 675 shares worth $67.1K. The position accounts for 0.02% of the portfolio, ranked #126.

RiverPark Advisors first reported a position in TMDX in Q3 2023 and has held it in 10 quarters since. The position peaked at $672K in Q2 2024. 414 funds tracked by Wall St. Rank hold TMDX as of Q1 2026.

RiverPark Advisors held 675 shares of Transmedics worth $67.1K as of Q1 2026.
RiverPark Advisors sold 9 Transmedics shares in Q1 2026, an estimated $1.17K.
Transmedics made up 0.02% of RiverPark Advisors's portfolio in Q1 2026, its #126 holding.
RiverPark Advisors first reported a position in Transmedics in Q3 2023 and has held it in 10 quarters since.
RiverPark Advisors's Transmedics position peaked at $672K in Q2 2024.
414 funds tracked by Wall St. Rank held Transmedics as of Q1 2026.

Based on RiverPark Advisors's 13F filing for Q1 2026, filed 14 May 2026.